白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2014年
4期
228-231,243
,共5页
李艳勃%王伟%杨颉%侯方%刘加秀
李豔勃%王偉%楊頡%侯方%劉加秀
리염발%왕위%양힐%후방%류가수
淋巴瘤%多环芳烃-DNA%细胞色素氧化酶P4501A1%谷胱苷肽硫转移酶M1%基因多态性
淋巴瘤%多環芳烴-DNA%細胞色素氧化酶P4501A1%穀胱苷肽硫轉移酶M1%基因多態性
림파류%다배방경-DNA%세포색소양화매P4501A1%곡광감태류전이매M1%기인다태성
Lymphoma%PAH-DNA%CYP1A1%GSTM1%Genetic polymorphisms
目的 探讨多环芳烃(PAH)-DNA加合物和代谢酶基因细胞色素氧化酶P4501A1(CYP1A1)与谷胱苷肽硫转移酶M1(GSTM1)基因多态性与淋巴瘤发病的关系.方法 通过竞争性酶联免疫吸附法测定54例淋巴瘤患者及34例对照组骨髓液中PAH-DNA加合物含量,采用限制性片段长度多态性PCR法(PCR-RFLP)测定上述标本CYP1A1、GSTM1基因多态性.结果 淋巴瘤患者骨髓液中PAH-DNA加合物含量为(2498±1 250) pg/ml,较对照组的(1 882±797) pg/ml增加,差异有统计学意义(t=0.006,P＜0.05);淋巴瘤患者GSTM1基因型缺失占85.2％,对照组占58.8％,差异有统计学意义(x2=7.73,P＜0.05),GSTM1基因型缺失者患淋巴瘤风险是GSTM1表达者的4.03倍(95％ CI1.51～10.76,P＜ 0.05);CYP1A1变异型是野生型患淋巴瘤风险的1.36倍(95％CI 0.56～ 3.31,P＞ 0.05),GSTM1缺失者PAH-DNA加合物水平≥2 200 pg/ml时患淋巴瘤的危险性增加(OR=9.53,95％CI 2.397～ 37.990,P＜ 0.05).结论 PAH-DNA加合物可能参与淋巴瘤的发病,GSTM1缺失与淋巴瘤发生有关,并且增加患淋巴瘤的风险.
目的 探討多環芳烴(PAH)-DNA加閤物和代謝酶基因細胞色素氧化酶P4501A1(CYP1A1)與穀胱苷肽硫轉移酶M1(GSTM1)基因多態性與淋巴瘤髮病的關繫.方法 通過競爭性酶聯免疫吸附法測定54例淋巴瘤患者及34例對照組骨髓液中PAH-DNA加閤物含量,採用限製性片段長度多態性PCR法(PCR-RFLP)測定上述標本CYP1A1、GSTM1基因多態性.結果 淋巴瘤患者骨髓液中PAH-DNA加閤物含量為(2498±1 250) pg/ml,較對照組的(1 882±797) pg/ml增加,差異有統計學意義(t=0.006,P＜0.05);淋巴瘤患者GSTM1基因型缺失佔85.2％,對照組佔58.8％,差異有統計學意義(x2=7.73,P＜0.05),GSTM1基因型缺失者患淋巴瘤風險是GSTM1錶達者的4.03倍(95％ CI1.51～10.76,P＜ 0.05);CYP1A1變異型是野生型患淋巴瘤風險的1.36倍(95％CI 0.56～ 3.31,P＞ 0.05),GSTM1缺失者PAH-DNA加閤物水平≥2 200 pg/ml時患淋巴瘤的危險性增加(OR=9.53,95％CI 2.397～ 37.990,P＜ 0.05).結論 PAH-DNA加閤物可能參與淋巴瘤的髮病,GSTM1缺失與淋巴瘤髮生有關,併且增加患淋巴瘤的風險.
목적 탐토다배방경(PAH)-DNA가합물화대사매기인세포색소양화매P4501A1(CYP1A1)여곡광감태류전이매M1(GSTM1)기인다태성여림파류발병적관계.방법 통과경쟁성매련면역흡부법측정54례림파류환자급34례대조조골수액중PAH-DNA가합물함량,채용한제성편단장도다태성PCR법(PCR-RFLP)측정상술표본CYP1A1、GSTM1기인다태성.결과 림파류환자골수액중PAH-DNA가합물함량위(2498±1 250) pg/ml,교대조조적(1 882±797) pg/ml증가,차이유통계학의의(t=0.006,P＜0.05);림파류환자GSTM1기인형결실점85.2％,대조조점58.8％,차이유통계학의의(x2=7.73,P＜0.05),GSTM1기인형결실자환림파류풍험시GSTM1표체자적4.03배(95％ CI1.51～10.76,P＜ 0.05);CYP1A1변이형시야생형환림파류풍험적1.36배(95％CI 0.56～ 3.31,P＞ 0.05),GSTM1결실자PAH-DNA가합물수평≥2 200 pg/ml시환림파류적위험성증가(OR=9.53,95％CI 2.397～ 37.990,P＜ 0.05).결론 PAH-DNA가합물가능삼여림파류적발병,GSTM1결실여림파류발생유관,병차증가환림파류적풍험.
Objective To explore the relationship between PAH-DNA adducts and CYP1A1,GSTM1 gene polymorphisms and lymphoma.Methods PAH-DNA adducts from bone marrow of lymphoma patients and control cases were determined by competitive ELISA.The genotypes of both CYP1A1 and GSTM1 were detected by PCR-based restriction fragment length polymorphisms (PCR-RELP).Results The level of PAH-DNA adducts in lymphoma patients [(2 498±1 250) pg/ml] was significantly higher than that in control [(1 882±797) pg/ml] (t =0.006,P ＜ 0.05).CYP1A1 mutant genotype and GSTM1 null genotype had increased risk of lymphoma,with OR being 1.36 (95 ％ CI 0.56-3.31,P ＞ 0.05),4.03 (95 ％ CI 1.51-10.76,P ＜ 0.05),respectively.GSTM1 null genotype individuals with PAH-DNA level higher (or equal) than 2 200 pg/ml had increased risk of lymphoma.Conclusions The content of PAH-DNA adducts and the occurrence of lymphoma may have a certain correlation.GSTM1 null genotype may be linked to lymphoma and increase the risk.
